Restoret drug enters late-stage clinical testing by June 30, 2024? | Binary | | | 7 months ago | |
Milestone achievements by EyeBio leading to additional payments by end of 2025? | Categorical | | | 7 months ago | |
Restoret drug market approval status by end of 2024? | Categorical | | | 7 months ago | |
Merck completes EyeBio acquisition by end of 2024? | Binary | | | 7 months ago | |
FDA approval for Restoret drug by end of 2024? | Binary | | | 7 months ago | |
Market reaction to Merck's ophthalmology sector expansion by end of 2024 | Categorical | | | 7 months ago | |
Does Merck's stock price increase within 6 months post-EyeBio acquisition? | Binary | | | 7 months ago | |
Merck's market share in ophthalmology by end of 2024? | Categorical | | | 7 months ago | |
Will Merck achieve FDA approval for Restoret by 2025? | Binary | | | 7 months ago | |
Will Merck acquire another ophthalmology company by 2025? | Binary | | | 7 months ago | |
What will be the outcome of the $1.7 billion contingent milestone payments in the Merck-EyeBio deal by 2025? | Categorical | | | 7 months ago | |
Efficacy results of EyeBio's Restoret drug in late-stage testing by mid-2025 | Categorical | | | 7 months ago | |
